JP2018513683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513683A5 JP2018513683A5 JP2017552483A JP2017552483A JP2018513683A5 JP 2018513683 A5 JP2018513683 A5 JP 2018513683A5 JP 2017552483 A JP2017552483 A JP 2017552483A JP 2017552483 A JP2017552483 A JP 2017552483A JP 2018513683 A5 JP2018513683 A5 JP 2018513683A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- polypeptide
- endogenous
- mhc
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 225
- 229920001184 polypeptide Polymers 0.000 claims description 221
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 221
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 91
- 108091008874 T cell receptors Proteins 0.000 claims description 89
- 239000002773 nucleotide Substances 0.000 claims description 84
- 125000003729 nucleotide group Chemical group 0.000 claims description 84
- 150000007523 nucleic acids Chemical group 0.000 claims description 80
- 230000001086 cytosolic effect Effects 0.000 claims description 57
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 40
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 39
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims description 29
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 28
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 27
- 230000001105 regulatory effect Effects 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 12
- 102000047279 human B2M Human genes 0.000 claims description 9
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 8
- 230000006801 homologous recombination Effects 0.000 claims description 8
- 238000002744 homologous recombination Methods 0.000 claims description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 4
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 claims description 4
- GTJASUYQSYEAFD-NPRBSQQLSA-N 102643-50-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)N)[C@@H](C)O)C1=CC=CC=C1 GTJASUYQSYEAFD-NPRBSQQLSA-N 0.000 claims description 3
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 3
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 3
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 108010050138 synthetic joining segment peptide Proteins 0.000 claims description 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 2
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 claims description 2
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 14
- 230000003796 beauty Effects 0.000 claims 5
- 108700005092 MHC Class II Genes Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 claims 2
- 108700031361 Brachyury Proteins 0.000 claims 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000003918 fraction a Anatomy 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 4
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 2
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 108010053491 HLA-DR beta-Chains Proteins 0.000 description 2
- 101150087698 alpha gene Proteins 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 102000048974 human HLA-B Human genes 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 108700043516 mouse H-2Kb Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143687P | 2015-04-06 | 2015-04-06 | |
| US62/143,687 | 2015-04-06 | ||
| US201562158804P | 2015-05-08 | 2015-05-08 | |
| US62/158,804 | 2015-05-08 | ||
| US201562186935P | 2015-06-30 | 2015-06-30 | |
| US62/186,935 | 2015-06-30 | ||
| PCT/US2016/026260 WO2016164492A2 (en) | 2015-04-06 | 2016-04-06 | Humanized t cell mediated immune responses in non-human animals |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085069A Division JP2020115896A (ja) | 2015-04-06 | 2020-05-14 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513683A JP2018513683A (ja) | 2018-05-31 |
| JP2018513683A5 true JP2018513683A5 (enExample) | 2019-05-23 |
| JP6796597B2 JP6796597B2 (ja) | 2020-12-09 |
Family
ID=56926255
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552483A Active JP6796597B2 (ja) | 2015-04-06 | 2016-04-06 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2020085069A Withdrawn JP2020115896A (ja) | 2015-04-06 | 2020-05-14 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2022122754A Withdrawn JP2022140609A (ja) | 2015-04-06 | 2022-08-01 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2023179453A Active JP7763820B2 (ja) | 2015-04-06 | 2023-10-18 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2024114035A Active JP7555515B1 (ja) | 2015-04-06 | 2024-07-17 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2025177694A Pending JP2026009189A (ja) | 2015-04-06 | 2025-10-22 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085069A Withdrawn JP2020115896A (ja) | 2015-04-06 | 2020-05-14 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2022122754A Withdrawn JP2022140609A (ja) | 2015-04-06 | 2022-08-01 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2023179453A Active JP7763820B2 (ja) | 2015-04-06 | 2023-10-18 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2024114035A Active JP7555515B1 (ja) | 2015-04-06 | 2024-07-17 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2025177694A Pending JP2026009189A (ja) | 2015-04-06 | 2025-10-22 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11259510B2 (enExample) |
| EP (2) | EP3280257B1 (enExample) |
| JP (6) | JP6796597B2 (enExample) |
| KR (2) | KR20240132525A (enExample) |
| CN (2) | CN113349159B (enExample) |
| AU (3) | AU2016246698B2 (enExample) |
| CA (2) | CA2980771C (enExample) |
| DK (1) | DK3280257T3 (enExample) |
| ES (1) | ES2954865T3 (enExample) |
| FI (1) | FI3280257T3 (enExample) |
| HR (1) | HRP20231039T1 (enExample) |
| HU (1) | HUE064168T2 (enExample) |
| IL (4) | IL318990A (enExample) |
| LT (1) | LT3280257T (enExample) |
| MX (2) | MX2017012829A (enExample) |
| NZ (1) | NZ736031A (enExample) |
| PL (1) | PL3280257T3 (enExample) |
| PT (1) | PT3280257T (enExample) |
| RS (1) | RS64540B1 (enExample) |
| RU (1) | RU2732628C2 (enExample) |
| SG (2) | SG11201707691WA (enExample) |
| SI (1) | SI3280257T1 (enExample) |
| SM (1) | SMT202300408T1 (enExample) |
| WO (1) | WO2016164492A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102295746B1 (ko) | 2011-10-28 | 2021-09-01 | 리제너론 파아마슈티컬스, 인크. | 유전자 변형된 주요 조직적합성 복합체 마우스 |
| RS61455B1 (sr) | 2011-10-28 | 2021-03-31 | Regeneron Pharma | Genetski modifikovani miševi t ćelijskog receptora |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| US9848587B2 (en) | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CN108366548B (zh) | 2015-11-20 | 2021-10-08 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| CN109640644B (zh) | 2016-06-03 | 2021-10-26 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| JP7621795B2 (ja) * | 2017-10-19 | 2025-01-27 | セレクティス | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| ES2987813T3 (es) | 2018-03-24 | 2024-11-18 | Regeneron Pharma | Métodos para identificar péptidos tumorales asociados al HLA |
| IL277355B2 (en) | 2018-03-26 | 2025-01-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| CA3098040A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| CN113454110B (zh) | 2018-10-23 | 2024-07-02 | 里珍纳龙药品有限公司 | Ny-eso-1 t细胞受体和其使用方法 |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12624086B2 (en) | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化凝固因子１２遺伝子座を含む非ヒト動物 |
| MX2021013218A (es) * | 2019-05-01 | 2021-12-10 | Pact Pharma Inc | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| US20210102942A1 (en) * | 2019-10-03 | 2021-04-08 | Regeneron Pharmaceuticals, Inc. | High-throughput method to screen cognate T cell and epitope reactivities in primary human cells |
| BR112022014461A2 (pt) | 2020-01-24 | 2022-09-13 | Regeneron Pharma | Antígeno preferencialmente expresso em receptores de células t de melanoma (prame) e métodos de uso dos mesmos |
| CN116981357A (zh) * | 2021-03-31 | 2023-10-31 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| WO2023092119A2 (en) | 2021-11-22 | 2023-05-25 | Ludwig Institute For Cancer Research Ltd | Methods for predicting responsiveness to a cancer therapy |
| CN113999873B (zh) * | 2021-12-31 | 2022-05-20 | 北京市疾病预防控制中心 | 一种基因修饰的非人动物的构建方法及其应用 |
| EP4215042A1 (en) * | 2022-01-21 | 2023-07-26 | Max-Delbrück-Centrum für Molekulare Medizin | A non-human mammal comprising in its genome at least two human leukocyte antigen (hla) class i alleles, methods of making such mammal and uses thereof |
| CN115074368B (zh) * | 2022-06-09 | 2023-08-08 | 澳门科技大学 | 一种耐药型类风湿性关节炎动物模型的构建及其应用 |
| CN120019068A (zh) * | 2022-08-12 | 2025-05-16 | 独创目标实验室 | 具有人源化γ和δTCR可变基因的经遗传修饰的非人类 |
| CA3265746A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF A HUMAN CELLULAR IMMUNE SYSTEM |
| IL320128A (en) | 2022-10-31 | 2025-06-01 | Regeneron Pharma | Methods for treating cancer using a combination of adoptive cell therapy and a targeted immunocytokine |
| WO2024112806A1 (en) * | 2022-11-21 | 2024-05-30 | Moonwalk Biosciences, Inc. | Generation and use of epigenetic maps for drug discovery |
| EP4688857A1 (en) | 2023-04-07 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a lymphotoxin beta receptor agonist |
| EP4720109A1 (en) | 2023-05-25 | 2026-04-08 | Regeneron Pharmaceuticals, Inc. | T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides |
| TW202520975A (zh) * | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2026006734A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development |
| WO2026006724A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Prame off-target peptides and uses thereof |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| GB202418716D0 (en) | 2024-12-19 | 2025-02-05 | Univ Oxford Innovation Ltd | Product |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958678A (en) | 1986-08-21 | 1999-09-28 | The Trustees Of Columbia University In The City Of New York | DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC ANIMALS HAVING TARGET LYMPHOCYTA TRANSDUCTION GENES. |
| US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| EP0910409A4 (en) | 1996-03-05 | 2003-03-19 | Scripps Research Inst | RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| WO2001027291A1 (en) | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7462486B2 (en) | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
| WO2002000933A2 (en) | 2000-06-23 | 2002-01-03 | Interleukin Genetics, Inc. | Screening assays for identifying modulators of the inflammatory or immune responses |
| US6911204B2 (en) * | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| PT1421115E (pt) * | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
| JP4087338B2 (ja) | 2001-11-15 | 2008-05-21 | キリンファーマ株式会社 | キメラ非ヒト動物 |
| WO2003068819A1 (en) | 2001-12-22 | 2003-08-21 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| WO2004042004A2 (en) | 2002-10-30 | 2004-05-21 | The Wistar Institute Of Anatomy And Biology | Mouse model for autoimmune disorders |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| US7745690B2 (en) | 2004-03-09 | 2010-06-29 | Nagoya Industrial Science Research Institute | Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| US20090304657A1 (en) | 2006-05-03 | 2009-12-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| CN101534859B (zh) * | 2006-09-08 | 2017-06-09 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
| WO2008051854A2 (en) | 2006-10-20 | 2008-05-02 | Trustees Of Boston University | A tunable genetic switch for regulating gene expression |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| EP2262898B1 (en) | 2008-03-07 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| WO2010107400A1 (en) | 2009-03-20 | 2010-09-23 | Agency For Science, Technology And Research | Genetically modified animal and method of obtaining the same |
| DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| EP2593551B1 (en) | 2010-07-15 | 2016-09-14 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| CN105950654B (zh) | 2010-11-27 | 2020-03-20 | 朱坚 | 一种人源化的转基因动物 |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| KR102295746B1 (ko) | 2011-10-28 | 2021-09-01 | 리제너론 파아마슈티컬스, 인크. | 유전자 변형된 주요 조직적합성 복합체 마우스 |
| RS61455B1 (sr) | 2011-10-28 | 2021-03-31 | Regeneron Pharma | Genetski modifikovani miševi t ćelijskog receptora |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| SI2818478T1 (sl) | 2011-10-28 | 2017-07-31 | Regeneron Pharmaceuticals, Inc. | Humanizirani il-6 in receptor il-6 |
| DK4389764T3 (da) | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf |
| US9848587B2 (en) * | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| SI2958937T1 (sl) * | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CA2902543A1 (en) * | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| AU2014249148B2 (en) | 2013-03-11 | 2020-04-02 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
-
2016
- 2016-04-06 MX MX2017012829A patent/MX2017012829A/es unknown
- 2016-04-06 EP EP16766106.5A patent/EP3280257B1/en active Active
- 2016-04-06 KR KR1020247028283A patent/KR20240132525A/ko active Pending
- 2016-04-06 SI SI201631742T patent/SI3280257T1/sl unknown
- 2016-04-06 HU HUE16766106A patent/HUE064168T2/hu unknown
- 2016-04-06 CA CA2980771A patent/CA2980771C/en active Active
- 2016-04-06 NZ NZ736031A patent/NZ736031A/en unknown
- 2016-04-06 CN CN202110308348.7A patent/CN113349159B/zh active Active
- 2016-04-06 CA CA3223798A patent/CA3223798A1/en active Pending
- 2016-04-06 US US15/564,723 patent/US11259510B2/en active Active
- 2016-04-06 SG SG11201707691WA patent/SG11201707691WA/en unknown
- 2016-04-06 CN CN201680030625.XA patent/CN107666828B/zh active Active
- 2016-04-06 IL IL318990A patent/IL318990A/en unknown
- 2016-04-06 PT PT167661065T patent/PT3280257T/pt unknown
- 2016-04-06 EP EP23175865.7A patent/EP4248744A3/en active Pending
- 2016-04-06 HR HRP20231039TT patent/HRP20231039T1/hr unknown
- 2016-04-06 JP JP2017552483A patent/JP6796597B2/ja active Active
- 2016-04-06 AU AU2016246698A patent/AU2016246698B2/en active Active
- 2016-04-06 FI FIEP16766106.5T patent/FI3280257T3/fi active
- 2016-04-06 PL PL16766106.5T patent/PL3280257T3/pl unknown
- 2016-04-06 RS RS20230771A patent/RS64540B1/sr unknown
- 2016-04-06 SG SG10201909320U patent/SG10201909320UA/en unknown
- 2016-04-06 RU RU2017137786A patent/RU2732628C2/ru active
- 2016-04-06 LT LTEPPCT/US2016/026260T patent/LT3280257T/lt unknown
- 2016-04-06 ES ES16766106T patent/ES2954865T3/es active Active
- 2016-04-06 IL IL297097A patent/IL297097B2/en unknown
- 2016-04-06 KR KR1020177032048A patent/KR102699643B1/ko active Active
- 2016-04-06 WO PCT/US2016/026260 patent/WO2016164492A2/en not_active Ceased
- 2016-04-06 SM SM20230408T patent/SMT202300408T1/it unknown
- 2016-04-06 DK DK16766106.5T patent/DK3280257T3/da active
- 2016-04-06 IL IL284809A patent/IL284809B2/en unknown
-
2017
- 2017-09-28 IL IL254775A patent/IL254775A0/en unknown
- 2017-10-05 MX MX2023002653A patent/MX2023002653A/es unknown
-
2020
- 2020-05-14 JP JP2020085069A patent/JP2020115896A/ja not_active Withdrawn
-
2022
- 2022-01-13 US US17/575,450 patent/US20220174921A1/en active Pending
- 2022-08-01 JP JP2022122754A patent/JP2022140609A/ja not_active Withdrawn
- 2022-08-26 AU AU2022221563A patent/AU2022221563B2/en active Active
-
2023
- 2023-10-18 JP JP2023179453A patent/JP7763820B2/ja active Active
-
2024
- 2024-07-17 JP JP2024114035A patent/JP7555515B1/ja active Active
-
2025
- 2025-05-06 AU AU2025203245A patent/AU2025203245A1/en active Pending
- 2025-10-22 JP JP2025177694A patent/JP2026009189A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7555515B1 (ja) | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 | |
| JP7261772B2 (ja) | ヒト化ｔ細胞補助受容体を発現するマウス | |
| KR102321909B1 (ko) | 유전자 변형된 ｔ 세포 수용체 마우스 | |
| CN113564188B (zh) | 制备主要组织相容性复合物基因修饰小鼠的方法 | |
| IL307238A (en) | Transgenic mice containing human components of the cellular immune system with an enhanced diversity of the TCRB repertoire | |
| JP2014532411A5 (enExample) | ||
| KR20260052083A (ko) | 유전자 변형 설치류 및 설치류 세포, 및 그의 용도 | |
| US20240099279A1 (en) | Genetically modified mice expressing components of human cellular immune system | |
| RU2023123775A (ru) | Генетически модифицированные мыши, содержащие гуманизированные компоненты клеточной иммунной системы с улучшенным разнообразием репертуара tcrβ | |
| HK40092669A (en) | Humanized t cell mediated immune responses in non-human animals | |
| HK1250884B (en) | Humanized t cell mediated immune responses in non-human animals |